18F-FDG PET/CT evaluation of patients with ovarian carcinoma
- 1 December 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 29 (12) , 1046-1051
Abstract
Purpose The role of 18F-FDG PET has been studied in ovarian carcinoma, but its sensitivity and specificity calculations are based on dedicated PET acquisition, not PET/CT in the majority of the published studies. Therefore, we were prompted to review our experience with PET/CT in the management of patients with ovarian carcinoma. Materials and methods This is a retrospective study of 43 women with ovarian carcinoma, 27–80 years old (average: 53.9±7.8), who had whole-body PET/CT at our institution from 1 January 2003 to 31 August 2006. We reviewed the patients' outcomes from medical records and compared them to the interpretation of the PET/CT scans. Sensitivity and specificity were calculated using a 2×2 table with pathology results (79.1% of the patients) or clinical follow-up (20.9% of the cases) as the ‘gold standard’. Confidence interval (CI) estimations were performed using the Wilson score method. Results All patients had advanced stage ovarian cancer and the study was requested for re-staging. A total of 60 scans were performed: 30 patients had one scan, nine patients had two scans and four patients had three scans. The administered doses of 18F-FDG ranged from 381.1 to 769.6 MBq (average: 569.8±73.3). PET/CT had a sensitivity of 88.4% (95% CI: 75.1–95.4) and a specificity of 88.2% (95% CI: 64.4–97.9) for detection of ovarian cancer. The SUV max of the detected lesions ranged from 3 to 27 (average: 9.4±5.9). The CA-125 tumor marker ranged from 3 to 935 kU/ml (average: 265.2) in patients with positive scans and 4–139 kU/ml (average: 17.1) in patients with negative scans. This difference was statistically significant (P value: 0.0242). Conclusion This study confirms the good results of 18F-FDG PET/CT for identification of residual/recurrent ovarian cancer, as well as for distant metastases localization. PET/CT should be an integral part in evaluation of patients with high-risk ovarian cancer or rising values of tumor markers (CA-125), prior to selection of the most appropriate therapy.Keywords
This publication has 36 references indexed in Scilit:
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- The diagnostic value of PET/CT for primary ovarian cancer—A prospective studyGynecologic Oncology, 2007
- Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancerGynecologic Oncology, 2007
- 18F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patientsEuropean Journal of Surgical Oncology, 2005
- Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancerInternational Journal of Clinical Oncology, 2005
- FDG-PET for management of cervical and ovarian cancerGynecologic Oncology, 2005
- Usefulness of FDG PET for Assessment of Early Recurrent Epithelial Ovarian CancerAmerican Journal of Roentgenology, 2002
- Positron Emission Tomography/Computed Tomography Imaging for the Detection of Recurrent Ovarian and Fallopian Tube Carcinoma: A Retrospective ReviewGynecologic Oncology, 2002
- 28. Accuracy of Qualitative and Semiquantitative Analysis of 18FDG Positron Emission Tomography Scans in the Evaluation of Primary and Metastatic LesionsClinical Positron Imaging, 2000
- Assessment of Primary and Metastatic Ovarian Cancer by Positron Emission Tomography (PET) Using 2-[18F]Deoxyglucose (2-[18F]FDG)Gynecologic Oncology, 1993